| __timestamp | Catalent, Inc. | Evotec SE |
|---|---|---|
| Wednesday, January 1, 2014 | 334800000 | 17990000 |
| Thursday, January 1, 2015 | 337300000 | 25166000 |
| Friday, January 1, 2016 | 358100000 | 27013000 |
| Sunday, January 1, 2017 | 402600000 | 42383000 |
| Monday, January 1, 2018 | 462600000 | 57012000 |
| Tuesday, January 1, 2019 | 512000000 | 66546000 |
| Wednesday, January 1, 2020 | 577900000 | 77238000 |
| Friday, January 1, 2021 | 687000000 | 105445000 |
| Saturday, January 1, 2022 | 844000000 | 156190000 |
| Sunday, January 1, 2023 | 831000000 | 169610000 |
| Monday, January 1, 2024 | 935000000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Catalent, Inc. and Evotec SE, two prominent players, have shown distinct trajectories over the past decade. From 2014 to 2023, Catalent's SG&A expenses surged by approximately 179%, reflecting its aggressive expansion strategy. In contrast, Evotec SE's expenses grew by nearly 843%, indicating a rapid scaling of operations. Notably, Catalent's expenses peaked in 2024, while Evotec's data for the same year remains unavailable, suggesting potential reporting delays or strategic shifts. This analysis underscores the importance of SG&A efficiency in driving profitability and competitive advantage. As the industry evolves, monitoring these trends will be key for investors and stakeholders alike.
Comparing SG&A Expenses: Pfizer Inc. vs Catalent, Inc. Trends and Insights
GSK plc vs Evotec SE: SG&A Expense Trends
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Catalent, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Evotec SE
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Comparing SG&A Expenses: Catalent, Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Catalent, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Evotec SE
Who Optimizes SG&A Costs Better? ADMA Biologics, Inc. or Evotec SE
Operational Costs Compared: SG&A Analysis of PTC Therapeutics, Inc. and Evotec SE
ACADIA Pharmaceuticals Inc. or Evotec SE: Who Manages SG&A Costs Better?